Triple combination therapy in patients infected with COVID-19

JRCT ID: jRCTs031190227

Registered date:27/02/2020

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: patients infected with COVID-19
• Date of first enrollment: 01/04/2020
• Target sample size: 50
• Study type: Interventional
• Intervention(s): oral administration of lopinavir, ritonavir and hydroxychloroquine with or without oseltamivir

Outcome(s)

• Primary Outcome: expected value and 95% CI of ratio of C-reactive protein before versus after the treatment
• Secondary Outcome: disappearance rate of COVID-19

Key inclusion & exclusion criteria

• Age minimum: >= 20age old
• Age maximum: Not applicable
• Gender: Both

Include criteria

positive result for COVID-19 detection test
fever above 37.5 degree Celsius, or pneumonia shadow on chest X-ray or CT-scan
hospital admission

Exclude criteria

past history of hypersensitivity to lopinavir, ritonavir, hydroxychloroquine or oseltamivir
pregnancy

Related Information

• Primary Sponsor: Tokue Yutaka
• Secondary Sponsor: Nakamura Tetsuya